The effect of acute administration of risperidone on local cerebral glucose utilization in the rat

European Journal of Pharmacology

Volumn 370, Issue 3, 1999, Pages 257-261

  Huang, Yn Ho ^a   Tsai, Shih Jen ^a,b   Huang, Hei Jen ^a   Sim, Cho Boon ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

14C 2 Deoxyglucose; Antipsychotic; Glucose utilization; Hippocampus; Mediodorsal thalamus; Risperidone

Indexed keywords

CARBON 14; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; THALAMUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DEOXYGLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; THALAMUS; TIME FACTORS;

EID: 0032963676     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00160-0     Document Type: Article

References (23)

1. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsycopharmacology. 1:1988;179-186.
2. Colangelo V., Di Grezia R., Passarelli F., Musicco M., Pontieri F.E., Orzi F. Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat. Brain Res. 768:1997;273-278.
3. Conrad A.J., Scheibel A.B. Schizophrenia and the hippocampus: the embryological hypothesis extended. Schizophr. Bull. 13:1987;577-587.
4. Engber T.M., Susel Z., Kuo S., Chase T.N. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J. Neurosci. 10:1990;3889-3895.
5. Giguere M., Goldman-Rakic P.S. Mediodorsal nucleus: areal, laminar, and tangential distribution of afferents and efferents in the frontal lobe of rhesus monkeys. J. Comp. Neurol. 277:1988;195-213.
6. Grant S., Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 48:1994;253-273.
7. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. 124:1996;74-86.
8. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology. 17:1997;44-55.
9. Jones E.G. Cortical development and thalamic pathology in schizophrenia. Schizophr. Bull. 23:1997;483-501.
10. Kadekaro M., Crane A.M., Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc. Natl. Acad. Sci. USA. 82:1985;6010-6013.
11. Kurachi M., Yasui S., Shibata R., Murata M., Hagino H., Tanii Y., Kurata K. Changes in local cerebral glucose utilization and dopamine metabolism in the rat brain following acute administration of haloperidol. Jpn. J. Psychiatry Neurol. 47:1993;921-928.
12. Leysen J.E., Janssen P.M., Gommeren W., Wynants J., Pauwels P.J., Janssen P.A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:1992;494-508.
13. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry. 55:1994;5-12. Suppl.
14. McCulloch J., Savaki H.E., Sokoloff L. Distribution of effects of haloperidol on energy metabolism in the rat brain. Brain Res. 243:1982;81-90.
15. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry. 47:1990;1023-1028.
16. Pizzolato G., Soncrant T.T., Larson D.M., Rapoport S.I. Stimulatory effect of the D2 antagonist sulpiride on glucose utilization in dopaminergic regions of rat brain. J. Neurochem. 49:1987;631-638.
17. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol. Exp. Ther. 271:1994;1058-1066.
18. Room P., Tielemans A.J., De Boer T., Van Delft A.M., Tonnaer J.A. The effect of the potential antipsychotic ORG 5222 on local cerebral glucose utilization in freely moving rats. Eur. J. Pharmacol. 205:1991;233-240.
19. Scheibel A.B., Conrad A.S. Hippocampal dysgenesis in mutant mouse and schizophrenic man: is there a relationship? Schizophr. Bull. 19:1993;21-33.
20. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
21. 14C ]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat J. Neurochem. 28:1977;897-916.
22. Tarazi F.I., Shirakawa O., Tamminga C.A. Low dose raclopride spares the extrapyramidal system in the rat brain from metabolic effects. Eur. J. Pharmacol. 232:1993;71-77.
23. Wan W., Ennulat D.J., Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res. 688:1995;95-104.